Compare Banco Santander SA (SAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs State Street SPDR S&P Biotech ETF — how do they compare? Banco Santander SA trades at $14.65 (market cap $214.37B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Banco Santander SA pays a 1.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SAN | XBI | |
|---|---|---|
Market Cap | $214.37B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $15.05 | $169.55 |
52-Week Low | $9.65 | $93.43 |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 14.47 and a net income margin of 26.25%, with Q1 2026 earnings beating expectations but Q2 missing. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence and diversifying the banking franchise.
Outlook is positive with analyst consensus at 'Moderate Buy' (64% buy ratings), though risks include volatile cash flows and high debt levels. Revenue growth is steady, but negative operating cash flow in 2024-2025 warrants monitoring. The stock offers value with solid profitability, but investors should weigh acquisition integration risks against expansion benefits.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
